Moderna (LTS:0A45) Investments And Advances : $4,743 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Moderna Investments And Advances?

Moderna's Investments And Advances for the quarter that ended in Dec. 2023 was $4,743 Mil.

Moderna's quarterly Investments And Advances declined from Jun. 2023 ($6,224 Mil) to Sep. 2023 ($5,359 Mil) and declined from Sep. 2023 ($5,359 Mil) to Dec. 2023 ($4,743 Mil).

Moderna's annual Investments And Advances increased from Dec. 2021 ($6,843 Mil) to Dec. 2022 ($8,360 Mil) but then declined from Dec. 2022 ($8,360 Mil) to Dec. 2023 ($4,743 Mil).

Moderna Investments And Advances Historical Data

The historical data trend for Moderna's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moderna Investments And Advances Chart

Moderna Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Investments And Advances

Get a 7-Day Free Trial

159.99

639.00

6,843.00

8,360.00

4,743.00

Moderna Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Investments And Advances	Get a 7-Day Free Trial															8,360.00	7,525.00	6,224.00	5,359.00	4,743.00

Moderna Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.

Moderna (LTS:0A45) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (LTS:0A45) » Definitions » Investments And Advances

Comparable Companies

Traded in Other Exchanges

MRNA:USA MRNA:Peru MRNA:Mexico 0QFd:UK 0QF:Germany M1RN34:Brazil MRNA:Austria

Address

200 Technology Square, Cambridge, MA, USA, 02139

Website

https://www.modernatx.com

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Moderna (LTS:0A45) Headlines

No Headlines